June 3, 2026 | Volume XV | Issue 22

Could cancer vaccines be next?

Fox News reports:


A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period.


The personalized mRNA cancer therapy, called intismeran autogene, combined with the cancer immunotherapy drug KEYTRUDA (pembrolizumab), is a collaboration between Merck and Moderna.


The results from the phase 2b KEYNOTE-942 study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.


After about a five-year follow-up, the combo drug was found to reduce the risk of melanoma...

Read More

More than $100 million was billed for medically questionable vascular procedures

Annie Waldman | ProPublica


Dozens of doctors are routinely performing risky vascular procedures in medical offices, generating tens of millions of dollars in Medicare payments for potentially unnecessary procedures, according to a federal report released last month.


The review, completed by the Office of the Inspector General at the Department of Health and Human Services, flagged nearly 140 doctors across the country as having “concerning” billing patterns.


The analysis parallels a 2023 ProPublica investigation that revealed how high Medicare reimbursements for office-based vascular treatments had fueled a surge of unnecessary procedures, putting patients at risk of amputation or even death. The inspector general’s study, which began in April 2024, cited ProPublica’s reporting and broadly confirmed its findings.


Millions of Americans have peripheral artery disease, a vascular disorder in which the buildup of plaque narrows arteries and blocks blood flow in the legs. While most treatments are safe, ProPublica’s investigation found that there has been widespread concern among medical experts that some doctors are overusing procedures on patients who may not need them.

Read More

AI adoption surges

Healthcare Dive reports:


Artificial intelligence adoption is accelerating rapidly in the healthcare sector, but clinicians are concerned that relying too heavily on the technology could lead them to lose critical thinking and decision-making skills, according to a survey published Tuesday by Wolters Kluwer Health.


Nearly three-quarters of doctors and 70% of nurses said they used AI at least once a week for work  — significantly higher than last year, when 38% of doctors and 46% of nurses...

Read More

New pancreatic cancer drug could buy more time

WBTV News - Charlotte


Daraxonrasib is an experimental, first-in-class targeted cancer therapy (also known as RMC-6236) developed by Revolution Medicines. It acts as a "molecular glue" to block overactive KRAS proteins, which are responsible for the growth of over 90% of pancreatic cancers.

View video HERE.

Publisher of Week in Review, Specialty Focus, FHIweekly & Game Changers